Other inverse agonists of ERRα are compound 29 and 50 developed by Janssen Pharmaceuticals, which show high selectivity for ERRα and have strong therapeutic potential for treating obesity and diabetes [38]. This evidence concerns the gene ESRRA and obesity due to melanocortin 4 receptor deficiency.